MCK Stock Recent News
MCK LATEST HEADLINES
McKesson's (MCK) first-quarter fiscal 2025 results are likely to reflect the solid display by the U.S. Pharmaceutical and Specialty Solutions segment, driven by higher prescription volume.
Beyond analysts' top -and-bottom-line estimates for McKesson (MCK), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended June 2024.
McKesson (MCK) reachead $629.09 at the closing of the latest trading day, reflecting a +1.96% change compared to its last close.
McKesson (MCK) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
In the latest trading session, McKesson (MCK) closed at $600.16, marking a +0.74% move from the previous day.
McKesson (MCK) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
McKesson (MCK) closed at $585.74 in the latest trading session, marking a +0.47% move from the prior day.
McKesson's (MCK) shares have risen 1.5% year to date on the back of solid fundamentals. Increasing volumes of prescription and specialty drugs boost the top line.
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
McKesson's (MCK) robust Biologics business raises optimism about the stock.